CNB Bank Acquires 198 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

CNB Bank boosted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) by 11.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,955 shares of the medical research company’s stock after buying an additional 198 shares during the quarter. CNB Bank’s holdings in Charles River Laboratories International were worth $556,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of CRL. Norges Bank bought a new position in shares of Charles River Laboratories International during the fourth quarter worth $191,481,000. Marshall Wace LLP raised its stake in Charles River Laboratories International by 50.3% during the fourth quarter. Marshall Wace LLP now owns 454,795 shares of the medical research company’s stock valued at $171,358,000 after purchasing an additional 152,258 shares in the last quarter. William Blair Investment Management LLC raised its stake in Charles River Laboratories International by 14.2% during the fourth quarter. William Blair Investment Management LLC now owns 1,076,250 shares of the medical research company’s stock valued at $405,509,000 after purchasing an additional 133,654 shares in the last quarter. Strs Ohio raised its stake in Charles River Laboratories International by 2,390.7% during the fourth quarter. Strs Ohio now owns 136,292 shares of the medical research company’s stock valued at $51,352,000 after purchasing an additional 130,820 shares in the last quarter. Finally, State Street Corp raised its stake in Charles River Laboratories International by 3.7% during the fourth quarter. State Street Corp now owns 2,030,795 shares of the medical research company’s stock valued at $765,163,000 after purchasing an additional 73,315 shares in the last quarter. Institutional investors and hedge funds own 93.06% of the company’s stock.

In related news, Director George Massaro sold 178 shares of the stock in a transaction that occurred on Monday, May 9th. The shares were sold at an average price of $230.96, for a total value of $41,110.88. Following the completion of the transaction, the director now directly owns 4,677 shares of the company’s stock, valued at approximately $1,080,199.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.10% of the company’s stock.

NYSE:CRL opened at $209.82 on Thursday. Charles River Laboratories International, Inc. has a fifty-two week low of $203.37 and a fifty-two week high of $460.21. The stock has a market capitalization of $10.66 billion, a P/E ratio of 25.56, a P/E/G ratio of 1.28 and a beta of 1.27. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.12 and a current ratio of 1.34. The company’s 50-day simple moving average is $238.75 and its 200-day simple moving average is $291.07.

Charles River Laboratories International (NYSE:CRLGet Rating) last released its quarterly earnings results on Wednesday, May 4th. The medical research company reported $2.75 earnings per share for the quarter, beating analysts’ consensus estimates of $2.71 by $0.04. The business had revenue of $913.93 million for the quarter, compared to analysts’ expectations of $908.64 million. Charles River Laboratories International had a net margin of 11.64% and a return on equity of 21.90%. The company’s revenue was up 10.8% compared to the same quarter last year. During the same period last year, the business earned $2.53 EPS. On average, research analysts forecast that Charles River Laboratories International, Inc. will post 11.6 EPS for the current year.

Several equities research analysts have recently weighed in on CRL shares. StockNews.com started coverage on shares of Charles River Laboratories International in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. Jefferies Financial Group downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating and reduced their target price for the company from $370.00 to $280.00 in a research note on Monday, April 25th. Wells Fargo & Company reduced their target price on shares of Charles River Laboratories International from $390.00 to $325.00 and set an “overweight” rating on the stock in a research note on Monday, April 25th. KeyCorp reduced their target price on shares of Charles River Laboratories International from $390.00 to $300.00 in a research note on Thursday, May 5th. Finally, Stephens set a $315.00 target price on shares of Charles River Laboratories International in a research note on Monday. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to MarketBeat, Charles River Laboratories International has an average rating of “Moderate Buy” and an average price target of $381.00.

About Charles River Laboratories International (Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Featured Stories

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLGet Rating).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.